Need professional-grade analysis? Visit stockanalysis.com
$66.79M
N/A
8
N/A
Price Chart
Risk-Adjusted Performance
Annovis Bio Inc (ANVS) Price Performance
Annovis Bio Inc (ANVS) trades on United States in USD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at $2.60, up 5.26% from the previous close.
Over the past year, ANVS has traded between a low of $1.22 and a high of $5.10. The stock has gained 32.0% over this period. It is currently 49.0% below its 52-week high.
Annovis Bio Inc has a market capitalization of $66.79M.
About Annovis Bio Inc
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 2/3 to treat alzheimer's disease, as well as in phase 3 to treat parkinson's disease; and is in phase 2 clinical trial to treat lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial to treat later stages of alzheimer's disease and dementia. The company was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Company Info
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- United States
- Currency
- USD
- Country
- United States
Financial Metrics
- Revenue (TTM)
- N/A
- EBITDA
- $-29,695,258
- Profit Margin
- N/A
- EPS (TTM)
- -5.34
- Book Value
- 0.65
Technical Indicators
- 52 Week High
- $5.50
- 52 Week Low
- $1.11
- 50 Day MA
- $2.84
- 200 Day MA
- $2.76
- Beta
- 1.31
Valuation
- Trailing P/E
- N/A
- Forward P/E
- N/A
- Price/Sales
- N/A
- Price/Book
- 5.08
- Enterprise Value
- $78.99M